Based on the data of the TIMER2 database (Figure 1A), the expression of PLEK2 was significantly upregulated in BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD (colon adenocarcinoma), ESCA (esophageal carcinoma), GBM (glioblastoma multiforme), HNSCC, KICH (kidney Chromophobe), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), READ (rectum adenocarcinoma), STAD (stomach adenocarcinoma), UCEC (uterine corpus endometrial carcinoma) compared with normal tissues. This evidence concerns the gene PLEK2 and bladder transitional cell carcinoma.